Marcus Hompesch

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Venues

Clinical pharmacology and therapeutics

Diabetes, obesity & metabolism

BMJ open diabetes research & care

ProSciento, Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

ProSciento, Inc Jan 01 2004

United States

President & CEO :: Executive Management

Profil Outpatient Trials GmbH

Germany

CEO :: Executive Management

Profil Institut fuer Stoffwechselforschung GmbH

Germany

Director of Clinical Research, COO, CFO :: Executive Management

Med IQ AG

Germany

CEO :: Executive Management

Klinikum Wuppertal

Germany

Physician :: Internal Medicine

Ruhr-Universitat Bochum

Germany

Scientific Associate :: Medical Biostatistics and Informatics

Publications

Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics (2024)
Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics 115 (6) (2024)
Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics 115 (6) (2024)
Wonjung Shin, Marcus Hompesch, JinHee Byeon, Seohyun Kang, Jaehyuk Choi, SeungJae Baek
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities. Diabetes, obesity & metabolism (2023)
Geoffrey A Walford, Kelly E Duncan, Moises Hernandez, Pavan Vaddady, Marcus Hompesch, Linda Morrow, S Aubrey Stoch
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer. Clinical pharmacology and therapeutics 112 (1) (2022)
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H Sorli, Alka Shaunik, Kun-Ho Yoon
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ open diabetes research & care 10 (1) (2022)
Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli, Ike Ogbaa, John Stewart, Linda Morrow
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ open diabetes research & care 9 (1) (2021)
Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard, Maria Ribadeneira, Wei Lu, Kiran Dole, Terry O'Reilly, Linda Morrow, Marcus Hompesch, Marc K Hellerstein, Kelvin Li, Lars Johansson, Patrick F Kelly
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. Diabetes, obesity & metabolism 23 (3) (2020)

Marcus Hompesch.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Marcus Hompesch